Billets de Michelle Dawson

Billet publié sur Twitter/X le 15/12/2013 21:21

Twitter/X Essai clinique clinicaltrials.gov Lien intégré au billet Termes sur l’autisme

Liens cités structurés

1 ressource citée

Essai clinique Récupéré Publication clinicaltrials.gov

Resilient Pharmaceuticals, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (2014). Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults. ClinicalTrials.gov. Resilient Pharmaceuticals.

Publication date
11/04/2014
Identifiant
NCT02008396
Auteurs
Resilient Pharmaceuticals, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Source
ClinicalTrials.gov
Type de référence
clinical_trial
Éditeur
Resilient Pharmaceuticals
Source de métadonnées
clinicaltrials.gov

Résumé

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing social anxiety in adults with autism. The main questions it aims to answer are: * Do two sessions of MDMA-assisted therapy reduce social anxiety? * What dose of MDMA is most effective at reducing social anxiety? Researchers will compare two blinded sessions of MDMA-assisted therapy to two blinded sessions of placebo with therapy. Participants will undergo three non-drug preparatory therapy sessions before the first blinded medication session. After each medication session, participants will undergo three non-drug integrative therapy sessions. In Stage 2, participants who received placebo with therapy in the first two blinded sessions will be able to undergo two sessions with MDMA-assisted therapy.